PURPOSE: Lower urinary tract symptom progression in community dwelling older men is not well described. MATERIALS AND METHODS: We evaluated 5,697 participants in Osteoporotic Fractures in Men, a prospective cohort study of community dwelling men 65 years old or older. We characterized lower urinary tract symptoms using the American Urological Association symptom index at 2 time points, including at study entry and at 2-year followup. Progression was examined in the overall cohort and within baseline symptom strata (symptom index 7 or less and 8 or greater) using descriptive statistics. RESULTS: At baseline mean +/- SD age was 73.5 +/- 5.8 years and mean symptom index score was 8.3 +/- 6.3 points. Mean and median total symptom index increased during followup by 1.1 +/- 5.0 and 1.0 points, respectively. Of the 3,092 men with a symptom index of 7 points or less at baseline 883 (29%) reported lower urinary tract symptoms progression (8 points or greater) at followup. The incidence of lower urinary tract symptom progression increased with advancing baseline age. Of the 2,605 men with a symptom index of 8 points or greater at baseline 622 (24%) reported progression of at least 4 points at followup. Of the 2,200 men with a baseline symptom index of 7 points or less and no history of benign prostatic hyperplasia or lower urinary tract symptom treatment 94% remained untreated, 2% reported benign prostatic hyperplasia surgery and 4% reported medication use at followup. CONCLUSIONS: Up to 29% of community dwelling older men with no or mild lower urinary tract symptoms will have clinically significant lower urinary tract symptoms within 2 years. These data help elucidate the natural history of lower urinary tract symptoms in the community and provide useful data to design clinical trials of lower urinary tract symptom prevention. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: Lower urinary tract symptom progression in community dwelling older men is not well described. MATERIALS AND METHODS: We evaluated 5,697 participants in Osteoporotic Fractures in Men, a prospective cohort study of community dwelling men 65 years old or older. We characterized lower urinary tract symptoms using the American Urological Association symptom index at 2 time points, including at study entry and at 2-year followup. Progression was examined in the overall cohort and within baseline symptom strata (symptom index 7 or less and 8 or greater) using descriptive statistics. RESULTS: At baseline mean +/- SD age was 73.5 +/- 5.8 years and mean symptom index score was 8.3 +/- 6.3 points. Mean and median total symptom index increased during followup by 1.1 +/- 5.0 and 1.0 points, respectively. Of the 3,092 men with a symptom index of 7 points or less at baseline 883 (29%) reported lower urinary tract symptoms progression (8 points or greater) at followup. The incidence of lower urinary tract symptom progression increased with advancing baseline age. Of the 2,605 men with a symptom index of 8 points or greater at baseline 622 (24%) reported progression of at least 4 points at followup. Of the 2,200 men with a baseline symptom index of 7 points or less and no history of benign prostatic hyperplasia or lower urinary tract symptom treatment 94% remained untreated, 2% reported benign prostatic hyperplasia surgery and 4% reported medication use at followup. CONCLUSIONS: Up to 29% of community dwelling older men with no or mild lower urinary tract symptoms will have clinically significant lower urinary tract symptoms within 2 years. These data help elucidate the natural history of lower urinary tract symptoms in the community and provide useful data to design clinical trials of lower urinary tract symptom prevention. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Alan R Kristal; Kathryn B Arnold; Jeannette M Schenk; Marian L Neuhouser; Noel Weiss; Phyllis Goodman; Colleen M Antvelink; David F Penson; Ian M Thompson Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Christian Temml; Clemens Brössner; Georg Schatzl; Anton Ponholzer; Leise Knoepp; Stephan Madersbacher Journal: Eur Urol Date: 2003-04 Impact factor: 20.096
Authors: J Kellogg Parsons; H Ballentine Carter; Alan W Partin; B Gwen Windham; E Jeffrey Metter; Luigi Ferrucci; Patricia Landis; Elizabeth A Platz Journal: J Clin Endocrinol Metab Date: 2006-04-11 Impact factor: 5.958
Authors: Varant Kupelian; John T Wei; Michael P O'Leary; John W Kusek; Heather J Litman; Carol L Link; John B McKinlay Journal: Arch Intern Med Date: 2006-11-27
Authors: J Kellogg Parsons; Jolee Mougey; Lori Lambert; Timothy J Wilt; Howard A Fink; Mark Garzotto; Elizabeth Barrett-Connor; Lynn M Marshall Journal: BJU Int Date: 2009-01-19 Impact factor: 5.588
Authors: Alan R Kristal; Kathryn B Arnold; Jeannette M Schenk; Marian L Neuhouser; Phyllis Goodman; David F Penson; Ian M Thompson Journal: Am J Epidemiol Date: 2008-02-07 Impact factor: 4.897
Authors: Melanie C Wuerstle; Stephen K Van Den Eeden; K Trudy Poon; Virginia P Quinn; John M Hollingsworth; Ronald K Loo; Steven J Jacobsen Journal: Arch Intern Med Date: 2011-10-10
Authors: Peter Weibl; Peter Laurinc; Roman Tomaškin; Tobias Klatte; Shahrokh Shariat F; Miroslav Helbich; Danica Fačkovcova; Peter Bujdák Journal: Wien Klin Wochenschr Date: 2015-03-28 Impact factor: 1.704
Authors: Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Andre B Araujo; Varant Kupelian; Susan A Hall; John B McKinlay Journal: J Urol Date: 2013-07-10 Impact factor: 7.450
Authors: Ryan P Kopp; Lynn M Marshall; Patty Y Wang; Douglas C Bauer; Elizabeth Barrett-Connor; J Kellogg Parsons Journal: Eur Urol Date: 2013-04-03 Impact factor: 20.096
Authors: Nancy N Maserejian; Shan Chen; Gretchen R Chiu; Carrie G Wager; Varant Kupelian; Andre B Araujo; John B McKinlay Journal: Urology Date: 2013-07-19 Impact factor: 2.649